FAP and neoplasm: This study provides the pre-clinical rationale that inhibition of FAP proteolytic activity and selected β1-integrin family members in combination may abrogate the invasive capabilities of pancreatic tumors by interfering with the architectural organization of tumor-associated ECMs and disrupting the tumor-stromal interactions.